Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week High – What’s Next?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $19.74 and last traded at $20.0580, with a volume of 408257 shares changing hands. The stock had previously closed at $18.71.

Analyst Upgrades and Downgrades

AMRX has been the topic of a number of recent analyst reports. Leerink Partners started coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price objective on the stock. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. Barclays upped their target price on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Finally, Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $20.14.

Amneal Pharmaceuticals Price Performance

The stock has a market capitalization of $6.23 billion, a PE ratio of 39.80 and a beta of 1.24. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm’s 50 day simple moving average is $17.95 and its 200 day simple moving average is $15.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, July 30th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In related news, Director John Kiely sold 50,000 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. This represents a 19.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jason Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock worth $7,216,567 in the last ninety days. 17.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tidal Investments LLC boosted its holdings in shares of Amneal Pharmaceuticals by 39.1% during the second quarter. Tidal Investments LLC now owns 31,723 shares of the company’s stock worth $549,000 after purchasing an additional 8,914 shares during the period. WINTON GROUP Ltd increased its holdings in Amneal Pharmaceuticals by 21.3% during the 2nd quarter. WINTON GROUP Ltd now owns 144,816 shares of the company’s stock valued at $2,507,000 after purchasing an additional 25,435 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Amneal Pharmaceuticals during the 2nd quarter valued at about $139,000. Arizona State Retirement System raised its position in Amneal Pharmaceuticals by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 44,011 shares of the company’s stock valued at $762,000 after purchasing an additional 837 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $225,000. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.